Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome
Myelodysplastic syndrome (MDS) is a hematological malignancy of undetermined etiology, possibly linked to chromosomal structural alterations, genetic mutations, presentation and carcinogenicity of variant antigens on cell surface, and the generation of pro-inflammatory microenvironment in the bone m...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-09-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023064307 |
| _version_ | 1797669928921202688 |
|---|---|
| author | Xinyu Guo Shunjie Yu Xiaotong Ren Lijuan Li |
| author_facet | Xinyu Guo Shunjie Yu Xiaotong Ren Lijuan Li |
| author_sort | Xinyu Guo |
| collection | DOAJ |
| description | Myelodysplastic syndrome (MDS) is a hematological malignancy of undetermined etiology, possibly linked to chromosomal structural alterations, genetic mutations, presentation and carcinogenicity of variant antigens on cell surface, and the generation of pro-inflammatory microenvironment in the bone marrow. Current drugs are unable to cure this disease, and therefore, decreasing the survival and proliferation of malignant cells to delay disease progression and extend the survival time of patients becomes the primary approach to management. In recent years, the immune system has received increasing attention for its potential role in the occurrence and development of MDS, leading to the emergence of immunoregulation as a viable treatment option. The current review provides a brief overview of pathogenesis of MDS and current treatment principles. In the meantime, the significance of immune proteins in treatment and prognosis of MDS is also discussed. |
| first_indexed | 2024-03-11T20:52:07Z |
| format | Article |
| id | doaj.art-c81cf3cb593f49b08e8ccdd7bf63f487 |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-03-11T20:52:07Z |
| publishDate | 2023-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-c81cf3cb593f49b08e8ccdd7bf63f4872023-10-01T05:58:53ZengElsevierHeliyon2405-84402023-09-0199e19222Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndromeXinyu Guo0Shunjie Yu1Xiaotong Ren2Lijuan Li3Department of Hematology, Tianjin Medical University General Hospital, Tianjin, Heping District 154 Anshan Road, Tianjin, ChinaDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin, Heping District 154 Anshan Road, Tianjin, ChinaDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin, Heping District 154 Anshan Road, Tianjin, ChinaCorresponding author. , Tianjin Medical University General Hospital, Tianjin 300052, China; Department of Hematology, Tianjin Medical University General Hospital, Tianjin, Heping District 154 Anshan Road, Tianjin, ChinaMyelodysplastic syndrome (MDS) is a hematological malignancy of undetermined etiology, possibly linked to chromosomal structural alterations, genetic mutations, presentation and carcinogenicity of variant antigens on cell surface, and the generation of pro-inflammatory microenvironment in the bone marrow. Current drugs are unable to cure this disease, and therefore, decreasing the survival and proliferation of malignant cells to delay disease progression and extend the survival time of patients becomes the primary approach to management. In recent years, the immune system has received increasing attention for its potential role in the occurrence and development of MDS, leading to the emergence of immunoregulation as a viable treatment option. The current review provides a brief overview of pathogenesis of MDS and current treatment principles. In the meantime, the significance of immune proteins in treatment and prognosis of MDS is also discussed.http://www.sciencedirect.com/science/article/pii/S2405844023064307Myelodysplastic syndrome (MDS)PathogenesisImmune checkpoint |
| spellingShingle | Xinyu Guo Shunjie Yu Xiaotong Ren Lijuan Li Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome Heliyon Myelodysplastic syndrome (MDS) Pathogenesis Immune checkpoint |
| title | Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome |
| title_full | Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome |
| title_fullStr | Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome |
| title_full_unstemmed | Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome |
| title_short | Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome |
| title_sort | immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome |
| topic | Myelodysplastic syndrome (MDS) Pathogenesis Immune checkpoint |
| url | http://www.sciencedirect.com/science/article/pii/S2405844023064307 |
| work_keys_str_mv | AT xinyuguo immunecheckpointsrepresentapromisingbreakthroughintargetedtherapyandprognosisofmyelodysplasticsyndrome AT shunjieyu immunecheckpointsrepresentapromisingbreakthroughintargetedtherapyandprognosisofmyelodysplasticsyndrome AT xiaotongren immunecheckpointsrepresentapromisingbreakthroughintargetedtherapyandprognosisofmyelodysplasticsyndrome AT lijuanli immunecheckpointsrepresentapromisingbreakthroughintargetedtherapyandprognosisofmyelodysplasticsyndrome |